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Abstract
The widely used atypical antipsychotic clozapine is a potent competitive antagonist at 5-HT3 receptors which may
contribute to its unique psychopharmacological profile. Clozapine binds to 5-HT3 receptors of various species. However, the
structural requirements of the respective binding site for clozapine remain to be determined. Differences in the primary
sequences within the 5-HT3A receptor gene in schizophrenic patients may result in an alteration of the antipsychotic
potency and/or the side effect profile of clozapine. To determine these structural requirements we constructed chimeras
with different 5-HT3A receptor sequences of murine and human origin and expressed these mutants in human embryonic
kidney (HEK) 293 cells. Clozapine antagonises recombinant mouse 5-HT3A receptors with higher potency compared to
recombinant human 5-HT3A receptors. 5-HT activation curves and clozapine inhibition curves yielded the parameters EC50
and IC50 for all receptors tested in the range of 0.6–2.7 mM and 1.5–83.3 nM, respectively. The use of the Cheng-Prusoff
equation to calculate the dissociation constant Kb values for clozapine revealed that an extracellular sequence (length 86 aa)
close to the transmembrane domain M1 strongly determines the binding affinity of clozapine. Kb values of clozapine were
significantly lower (0.3–1.1 nM) for receptors containing the murine sequence and higher when compared with receptors
containing the respective human sequence (5.8–13.4 nM). Thus, individual differences in the primary sequence of 5-HT3
receptors may be crucial for the antipsychotic potency and/or the side effect profile of clozapine.
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Introduction
Schizophrenia is a severe psychiatric illness with hallucinations,
delusions, poverty of thought and emotions, social withdrawal and
cognitive deficits as leading symptoms. A dysregulation of the
dopaminergic neurotransmitter system plays an important role in
the pathophysiology of schizophrenia. However, current research
indicates additional dysfunctions of glutamatergic, GABAergic and
also serotonergic (5-HT) neurotransmission [1,2]. Most antipsy-
chotic agents antagonise the actions of endogenous dopamine at
type 2 dopamine (D2) receptors in the brain. In contrast, the
widely used atypical antipsychotic clozapine has a relatively poor
affinity to D2 receptors, but exerts also antagonistic effects at
histamine receptors, muscarinic acetylcholine receptors, a-adre-
noceptors and serotonin receptors [3,4]. Within the 5-HT receptor
subtypes clozapine is a potent antagonist at 5-HT2, 5-HT3A,
5-HT6 and 5-HT7 receptors [5].
The dopamine hypothesis of schizophrenia suggests an enhanced
mesolimbic activity of dopaminergic neurotransmission [6,7].
Behavioural, neurochemical and electrophysiological investigations
indicate that 5-HT3 receptors modulate dopaminergic activity in
mesolimbic and nigrostriatal pathways [8,9]. 5-HT3 receptor
activation enhanced dopamine release from slices of rat nucleus
accumbens [10], striatum [11,12], and increased the activity of
dopaminergic neurons in the ventral tegmental area [13]. These
data suggest that 5-HT3 receptor antagonists could mimic certain
inhibitory effects of antipsychotic drugs. It may therefore be
assumed that the antagonistic effects of clozapine mediated via
5-HT3 receptors might contribute to its antipsychotic potential.
Functional 5-HT3 receptors can only be formed by 5-HT3A
subunits, alone or in combination with the 5-HT3B subunit [14].
The functional antagonism of antipsychotics at the 5-HT3A
receptor may have important physiological implications. In the
CNS, the functional properties of presynaptic 5-HT3A receptors
may differ from those of postsynaptic 5-HT3A receptors.
Presynaptic 5-HT3A receptors are responsible for the elevation
of intracellular Ca2+ and modulate the release of several
neurotransmitters such as glutamate, dopamine, GABA, norepi-
nephrine and 5-HT [15,16,17]. Postsynaptic 5-HT3A receptors
mediate fast synaptic neurotransmission in the CNS [18,19]. The
reduction of these Na+ and Ca2+ fluxes by antipsychotics may be
involved in their inhibitory effect on neuronal discharge activity,
and modulation of postsynaptic 5-HT3A receptors could alter
learning and memory processes [17,20,21,22].
The primary amino acid sequence of the receptor determines
the affinity of agonists or antagonists for the specific binding site.
The effects of the competitive 5-HT3A receptor antagonist
clozapine are affected by either changes in the primary sequences
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of the 5-HT3A receptor gene encoding for the binding site or by
modulation of the binding affinity of the endogenous agonist 5-HT
to the receptor. It is therefore possible that variations in the 5-HT3
receptor gene of schizophrenic patients may result in an alteration
of the antipsychotic potency and/or the side effect profile of
clozapine.
Functional antagonistic properties of the atypical antipsychotic
clozapine have previously been reported for recombinant mouse
5-HT3A receptors with even higher potency (IC50 = 10 nM;
[23,24]) compared to recombinant human 5-HT3A receptors
(IC50 = 680 nM; [5]). To investigate the structural domains
involved in the ligand recognition site for clozapine and activation
and deactivation kinetics of 5-HT3A receptors we constructed 5
different receptor chimeras consisting of different murine and
human sequences. The antagonistic effects of clozapine and those
of 5-HT on receptor kinetics were tested by monitoring cation
currents through these different functional receptor mutants.
Materials and Methods
Cell culture
Native human embryonic kidney cells (HEK 293 cells) were
purchased (German collection of cell cultures, Braunschweig,
Germany) and HEK 293 cells stably expressing the human
5-HT3A receptor [25] or the murine 5-HT3A receptor, respective-
ly, were grown as previously described [5].
Transfection
cDNAs encoding the human 5-HT3A subunit (nucleotides
217–1663, GenBank accession no. D49394, and chimeras were
cloned into pCDM8 plasmid vectors [14]), the murine 5-HT3A
subunit was cloned into a pCDM6xl plasmid vector. HEK 293
cells were stably transfected with plasmids containing cDNA for the
human 5-HT3A or with cDNAs for the murine 5-HT3A subunits.
Chimeric 5-HT3A receptor subunits or the P391R mutant carrying
an intracellular mutation [26] were transiently transfected. A plasmid
(pCDM8, pRK5) encoding for the cDNA of green fluorescent protein
(GFP) as an expression marker was co-transfected. Exponentially
growing HEK 293 cells (26106 cells) were transfected with chimeric
or P391R DNA and GFP DNA by electroporation (BTX
Electroporation System, Electro Cell Manipulator 600, San Diego,
CA). Cells were harvested 12–18 h before transfection. After
harvesting from a 206100 mm culture dish, the cells were
resuspended in an electroporation buffer (975 ml, distilled H20
containing (in mM) 50 K2HPO4, 20 K
+-acetate, pH 7.35) and a
magnesium-sulfate solution (25 ml distilled water containing 1 M
MgSO4, pH 6,7) before transfection plasmids containing cDNAs for
the 5-HT3A receptor subunits (5 mg) and for GFP (3 mg) were added
to the cell suspension. Electroporation was performed at 300 V and
1 mF with a pulse time of 30–45 ms. Transfected cells were replaced
in 10635 mm culture dishes with supplemented medium and
incubated (5% CO2, 95% air, and 100% relative humidity, 37uC)
for 12–18 h before the experiments. After the incubation period,
5–30% of the transfected cells expressed GFP, which is soluble in the
cytoplasma, and more than 50% of the green fluorescent cells yielded
5-HT-induced inward currents. The kinetics of 5-HT3 receptor-
mediated currents in HEK 293 cells with cotransfected GFP were
identical to those in preparations without GFP cDNA co-transfection.
Construction of unique restriction sites in the human and
mouse 5-HT3 receptor
To create unique restriction sites we introduced a BstEII site in
the human 5-HT3 receptor subunit [27], corresponding to the
BstEII site in the mouse 5-HT3 receptor mRNA at position 531
[28]. Additionally, in the murine 5-HT3 receptor subunit a SgrA1
restriction site was introduced corresponding to the SgrA1 site in
the human 5-HT3 receptor mRNA at position 935 and an XhoI
multicloning site was introduced in the mouse 5-HT3 receptor at
position 1541 corresponding to the XhoI multicloning site in the
human gene. Mutations were performed with the QuikChange
Site-directed Mutagenesis Kit (Stratagene, USA). All mutations
were silent.
Construction of chimeric receptors
To construct chimeric receptors the cDNAs of both the human
and the murine receptor subunits were digested with BstEII and
HindIII, SgrA1 and HindIII, SgrA1 and BstEII, SgrA1 and XhoI,
BstEII and XhoI, respectively. The digestion products were
resolved on 1% or 1.5% agarose gels. The resulting small murine
digestion fragments were subcloned in the corresponding human
vector fragments. The chimeric cDNAs were sequenced on both
strands to verify integrity of the mutants.
Structure of 5-HT3 receptor chimeras composed of
human and murine 5-HT3A sequences
5-HT3A receptors are pentameric assemblies of subunits
consisting of extracellular, transmembrane, and cytoplasmic
domains [29]. To investigate the molecular determinants for the
differences in receptor kinetics, affinity and antagonistic potency of
clozapine we constructed different chimeric receptors between
human and murine 5-HT3 receptor sequences. We created five
chimeric receptors (Fig. 1 and 2), which contained the sequence
between the amino terminus ( = restriction site HindIII) and
restriction site of BstEII (defined as sequence 1) and the sequence
between restriction site BstEII and SgrA1 (defined as sequence 2).
Sequence 1 and 2 together belong to the extracellular domain and
form the ligand binding site. The sequence between restriction site
of SgrA1 and the carboxyl-terminal domain ( = restriction site
XhoI; defined as sequence 3; Fig. 2) belongs to the transmembrane
and cytoplasmic domain. For clarity, human, murine receptors
and chimeras were indicated as a combination of the numbers for
the three different sequences where human sequences are marked
in bold and murine sequences are marked in italics. The prefix
‘‘H’’, ‘‘M’’ and ‘‘C’’ indicates human, murine and chimeric
receptors, respectively: human 5-HT3 receptor =H123, murine
5-HT3 receptor =M123, chimeras are either C123, C123, C123,
C123 or C123. Fig. 1A shows the different receptor chimeras and
the respective sequences consisting of human and mouse 5-HT3
receptor composites. The expression plasmid carrying the P391R
mutant [26] was kindly provided by Sarah Lummis, Cambridge,
UK.
Concentration clamp recordings
5-HT-induced inward Na+ currents were recorded from lifted
HEK cells transiently transfected with the human, murine 5-HT3A
receptor and chimeras in the whole-cell voltage clamp configura-
tion under visual control using an inverted microscope (Zeiss, Jena,
Germany) as previously described [30]. Cells were kept in a bath
solution containing 140 mM NaCl, 2.8 mM KCl, and 10 mM
HEPES, pH 7.2. Patch electrodes were pulled from borosilicate
glass (Hilgenberg, Malsfeld, Germany) using a horizontal pipette
puller (Zeitz Instruments, Augsburg, Germany) to yield pipettes
with a resistance of 3–6 MV. Pipettes were filled with a solution
containing 130 mM CsCl, 2 mM MgCl2, 2 mM CaCl2, 2 mM
ATP, 0.2 mM Tris-GTP, 10 mM glucose, 10 mM HEPES, and
10 mM EGTA, pH 7.2. After the whole-cell configuration was
established, the cells were lifted from the glass substrate and
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10 mM 5-HT were applied using a fast superfusion device. We
applied these concentrations since 10 mM 5-HT were used for the
determination of the IC50 value for the inhibition of the 5-HT
response by psychopharmacological drugs in our previous study
[5], which was in the low micromolar range. For control
experiments a piezo translator-driven double-barrelled application
pipette was used to expose the lifted cell either to 5-HT-free or 5-
HT-containing solution. A 2 s 5-HT pulse was delivered every 90 s.
The stock solutions (10 mM or 10 mM) of clozapine were diluted
with bath solution to the desired concentration. To control for any
possible confounding solvent effects, currents were recorded with
0.1% ethanol in 5-HT-free or 5-HT-containing solutions. Current
signals were recorded at a holding potential of 250 mV with an
EPC-9 amplifier (Heka, Lamprecht, Germany) and were analysed
using the Heka 8.5 PulseFit and IgorPro v. 5.04B (Wavemetrics,
Lake Oswego, OR, USA) software on a Power Macintosh G3
computer. In experiments with clozapine, only results from stable
cells entered the final analysis, that is, showing at least 50% recovery
of responses to 5-HT following the removal of drugs. In some cells,
recovery was not 100% because of rundown (see frequent activation
experiments). To compensate for this effect the % antagonism at
each concentration was based on both the control and the recovery
current by assuming a linear time course for the rundown. Data are
shown as mean 6SEM. We recorded from a total of 120 cells.
Measurements were performed as independent experiments relative
to control and recovery.
Dose-response curves and the respective EC50 and IC50 values
were calculated by the four parameter logistic equation for
agonists: I = Imax (agonist)
Hill/(agonist+EC50Hill) and for antago-
nists: I = Imax (antagonist)
Hill/(antagonist+IC50Hill). The corrected
binding affinity of clozapine Kb was calculated using the Cheng-
Prusoff equation [31]: Kb= IC50/(1+[agonist]/EC50). A full dose-
response curve was determined from every cell and the EC50 and
IC50 values with the respective Hill coefficients were calculated.
These values from each single dose-response curve were averaged
thereafter. Thus, the reported means 6SEM result from different
cells after averaging. For the figures of the dose-response curves we
fitted the curve according to the average value for each respective
concentration. Because the charge represents the most appropriate
measure for receptor activation the IC50 and EC50 values for
charge entered the Cheng-Prusoff equation for Kb analysis.
Statistical analysis
EC50 and IC50 values, respectively, were calculated for each
recorded cell and tested for statistical significance by one-way
ANOVA using Bonferroni correction for multiple comparison. For
testing the rundown of the different 5-HT3 receptors after multiple
Figure 1. Amino acid sequence of cloned cDNA encoding the human and mouse 5-HT3A receptor channel subunit. Marked in red:
mismatches of the amino acid sequence. Marked in green: Restriction sites for BstEII and SgrA1 representing switching points of the chimeric
receptors. C-C: Cys-loop. M1–M4 transmembrane segments.
doi:10.1371/journal.pone.0006715.g001
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activations, the values of the last 5 5-HT applications (22nd–26th
application) entered statistical analysis. A value of p,0.05 was
considered as statistically significant. Statistical analysis was
performed using the SPSS 14.0 for Windows (SPSS Inc., Chicago,
IL, USA).
Chemicals and Drugs
Clozapine was purchased from Sigma (Munich, Germany) and
stock solutions (10 mM) were prepared in pure ethanol. Thus, the
maximum ethanol concentration in experiments using drug
concentrations of 10 mM was less than 0.1%. Serotonin was
purchased from Sigma and dissolved in water.
Results
Rundown kinetics of recombinant human and murine
5-HT3 receptors after multiple activation
5-HT3 receptor activity is very sensitive to the presence of
external Ca2+ as currents decline when Ca2+ concentration
increases [32]. Therefore, 5-HT-activated currents were recorded
in a HEPES-buffered Ca2+-free solution. First, we characterized
the kinetics of H123 and M123 (see also Table 1). At a holding
potential of 250 mV, 5-HT (10 mM) applied for 2 s evoked
inward currents which rose (H123: ton = 20.161.5 ms, n= 38;
M123: ton = 28.561.6 ms, n= 36; Fig. 3A) to a peak of
3806.16272.5 pA and 340.3630.3 pA for H123 and M123,
respectively, and induced an incomplete receptor desensitization
(H123: tdes1 = 1879.76164.3 ms, tdes2 = 1359.46161.7 ms; M123:
tdes1 =2647.66132.9 ms, tdes2 =2514.86148.3 ms;Fig. 3A). Because
of these characteristics of receptor desensitization, true steady-state
responses could not be determined. Hence, steady-state currents
have been defined as the last 10 ms of 5-HT application (see also
[5,25]). After the removal of 5-HT, receptor currents deactivated
completely with a time constant of toff = 1977.06117.7 ms and
toff = 5937.46730.1 ms for H123 and M123, respectively (Fig. 3A).
The frequent activation of human 5-HT3 receptors is accompa-
nied by constant rundown kinetics as previously shown [5]. In the
present study, multiple 5-HT applications (26 applications within
40 min) reduced peak currents through H123 to 74% (n= 4),
accelerated tdes1 and tdes2 to 64% and 73%, respectively, and
reduced the steady-state current to 37% (Fig. 3B, C).
Rundown kinetics of M123 are significantly less pronounced
(after 26 applications, peak currents were reduced to 84%, plateau
currents to 76% and tdes1 and tdes2 were even slowed down to
110% and 109%, respectively; Fig. 3B, C). Since rundown affects
plateau currents and desensitization of H123 more effectively than
those of M123, the calculation of charge thus represents a very
sensitive parameter for receptor activity. Fig. 3B (right) demon-
strates the strong rundown of H123 charge to 42% of control in
comparison to the reduction of M123 charge to 72%. The
parameter charge is therefore a suitable tool to investigate the
molecular determinants for the differences in receptor kinetics by
constructing human/murine receptor chimeras.
In the present study, we found a 99.4% recovery for human
and a 97.9% recovery for murine receptors of the peak amplitude
when two 5-HT applications for 2 sec were separated by a 25 sec
interval (data not shown). These results are consistent with
previous reports [33,34] which found a nearly complete recovery
after 25 to 60 sec. Thus, using an interval of 90 sec between two
Figure 2. Different receptor chimeras and the respective sequences consisting of human and mouse 5-HT3A receptor composites.
For clarity, human, murine receptors and chimeras are indicated as a combination of the numbers for the three different sequences, where human
sequences are marked in bold and murine sequences are marked in italics. The prefix ‘‘H’’, ‘‘M’’ and ‘‘C’’ indicates human, murine and chimeric
receptors, respectively: human 5-HT3 receptor =H123, murine 5-HT3 receptor =M123, chimeric receptors are C123, C123, SH1,C123, C123 and C123.
doi:10.1371/journal.pone.0006715.g002
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5-HT applications as in the present study should not affect
receptor desensitization and prevent consecutive accumulation of
desensitization. Furthermore, a similar rundown was obtained for
both human and murine 5-HT3 receptors after only two 5-HT
applications separated by a 40 min interval (data not shown). As
such, the rundown cannot be simply attributed to an enhance-
ment of receptor desensitization induced by multiple 5-HT
applications.
Rundown kinetics for chimeras
All chimeras tested produced functional currents upon 5-HT
activation. However, the currents through the different receptor
chimeras showed a strong variation in kinetics (Table 1) and
rundown (Fig. 4A, B, C ; Table 2, 3). Whereas these differences
were only marginally for peak currents (except for C123 and C123
where amplitudes were significantly reduced to 58% and 58% of
control, respectively), analysis of charge showed more pronounced
variation between all receptor types (Fig. 4B, C). Concomitantly,
charge variations between the different receptor types displayed a
good correlation to kinetic parameters such as desensitization,
plateau current and deactivation (Fig. 4C). The M123 receptor
currents were less affected by multiple 5-HT applications, showing
only a minor rundown. Statistical analysis revealed that the charge
of all other receptor types was strongly reduced in comparison to
M123. No significant difference could be found between either
C123, H123, C123 and C123, C123, C123, respectively.
However, each of the receptor types C123, C123 and C123
showed a significantly reduced charge compared to C123, H123
and C123.
Functional antagonistic properties of the atypical
antipsychotic clozapine against H123 and M123 currents
Human and murine 5-HT3 receptors showed almost identical
affinity to 5-HT [25] which was also confirmed in the present
study. Peak amplitude and charge of currents through H123 and
M123 were concentration-dependently increased (Fig. 5A). Clo-
zapine antagonised 5-HT-activated currents through human and
murine 5-HT3 receptors with different potencies [5,24]. In the
present study, clozapine was significantly more potent against
M123 whereas the peak amplitude and charge of H123 were
reduced less effectively (Fig. 5B). As such, the structural domains
involved in the ligand recognition for clozapine can be identified
by human/murine chimeras.
5-HT-induced currents through chimeric receptors
All chimeric receptors were dose-dependently activated by 5-
HT with an EC50 in the range of 1.22 mM to 4.92 mM and
0.65 mM to 2.76 mM for peak and charge, respectively (Fig. 6A, B;
Table 4, 5). For each dose-response curve values were normalized
to the responses induced by 300 mM 5-HT. The EC50 for the peak
current through the chimera C123 significantly differed from all
other receptor types, that from C123 only from M123 and C123.
The EC50 for the peak current for C123, M123, C123, C123 and
H123 were comparable with regard to the EC50 for charge: C123
and C123 showed the lowest affinity for 5-HT with an equal EC50
which differed significantly from those of all other receptor types.
The dose-response curves for 5-HT of C123, C123, M123, H123
and C123 yielded a similar EC50 with no significant difference
(Fig. 6 A, B).
Antagonistic properties of clozapine against chimeric
and mutant receptors
All 5-HT-induced currents through chimeric receptors were
dose-dependently reduced by clozapine in a competitive manner,
however, with different potencies (Fig. 7 and 8; Table 6, 7).
Clozapine was most potent against 5-HT-induced currents of C123
receptors and showed lowest affinity to antagonise currents through
H123 receptors (Fig. 7 and 8). Interestingly, clozapine exerts higher
antagonistic potencies against those receptors carrying the murine
sequence 2, whereas clozapine antagonism was less potent against
receptors with a corresponding human sequence.
Recently, a single point mutation in the cytoplasmic domain of
the 5-HT3 has been identified in individuals diagnosed with
schizophrenia [35]. To investigate whether a mutation located at
the intracellular site of the receptor affects competitive antago-
nism, we tested the pharmacological potency of clozapine against
the human P391R mutant [26]. Interestingly, clozapine reduced
5-HT-evoked currents through this transiently transfected receptor
with higher potency as for H123 (IC50 for peak: 4.8160.18 nM
(Hill =21.35); charge: 5.9160.1 nM (Hill = 1.21); Fig 7 and 8).
Table 1. Kinetics of human, murine and chimeric 5-HT3A receptors after first application of 5-HT for 2 s.
Peak (pA) Charge (pC) ton (ms) tdes1 (ms) tdes1 (ms) toff (ms) plateau (pA)
C123 21045.8 24.49 18.3 2053.7 1599.4 3951.5 2684.3
6210.9 61.27 62.9 6149.7 6198.1 6234.5 6171.5
C123 2886.7 23.01 59.7 2190.1 1726.5 2355.9 2534.6
6142.2 60.8 63.1 6232.7 6274.6 6184.1 6122.5
C123 22446.1 210.6 8.7 2266.8 1580.8 3459.6 21628.8
6252.5 61.51 60.6 6161.9 6212.0 6254.0 6230.9
C123 22003.4 27.5 10.7 2310.6 1456.2 2272.6 21430.2
6193.7 60.9 61.6 6141.1 6246.5 6628.3 6158.6
C123 21667.1 210.9 39.5 2384.4 2131.8 2910.3 21517.9
6256.8 61.9 65.3 6179.6 6199.7 6302.2 6249.9
M123 2340.3 22.1 28.5 2647.6 2514.8 5937.4 2294.3
630.3 60.3 61.6 6132.9 6148.2 6730.1 631.7
H123 23806.1 210.1 20.1 1879.7 1359.4 1977.0 22047.4
6272.5 61.2 61.5 6164.3 6161.7 6117.7 6235.0
doi:10.1371/journal.pone.0006715.t001
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Figure 3. Rundown kinetics of recombinant human and murine 5-HT3A receptors after multiple activation. (A) Representative current
traces for human (left) and murine (right) receptors showing currents after the first and 26th application of 5-HT. Records were obtained from the
same cell. (B) Repeated 5-HT applications (26 applications within 40 min) reduced peak currents (left) and charge (right) through H123 (filled circles)
and M123 (open circles) differently. Since rundown affects plateau currents and desensitization of H123 more effectively than those of M123, the
calculation of charge thus represents a very sensitive parameter for receptor activity. (C) Bar diagram showing the change in plateau currents, tdes1
and tdes2 after 22 to 26 5-HT applications (mean 6 SEM). Values were normalized to current kinetics evoked by the first application of 5-HT.
doi:10.1371/journal.pone.0006715.g003
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Figure 4. (A) Rundown kinetics for chimeras. Representative current traces for human, murine receptors and chimeras showing currents after the first
and 26th application of 5-HT. Records were obtained from the same cell. All chimeras tested produced functional currents upon 5-HT activation.
However, the currents through the different receptor chimeras showed a strong variation in kinetics and rundown. (B) Repeated 5-HT-applications (26
applications within 40 min) reduced peak currents (left) and charge (right). Differences were only marginally for peak currents, whereas analysis of
charge showed more pronounced variation between all receptor types. (C) Charge variations between the different receptor types displayed a good
correlation to kinetic parameters such as desensitization, plateau current and deactivation.
doi:10.1371/journal.pone.0006715.g004
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Calculation of the dissociation constant Kb of clozapine
using the Cheng-Prusoff equation
The agonist activation curves and antagonist inhibition curves
in the presence of a fixed agonist concentration [A] have been
fitted to logistic functions to yield the parameters EC50 and IC50.
Kb for all receptors were obtained with the Cheng-Prusoff estimate
(Table 8). The lowest Kb for clozapine were calculated for
receptors containing the murine sequence 2 (0.3–1.1 nM). When
5-HT3 receptors contained the human sequence 2, clozapine
affinity to the binding site was less potent and Kb ranged from 5.8–
13.4 nM. These data demonstrate that the sequence between
restriction site BstEII and SgrA1 (defined as sequence 2) of 5-HT3
receptors is important for the binding affinity of clozapine.
The calculation of the dissociation constant of clozapine for the
P391R mutant revealed a Kb of 1.3 nM. The EC50 for 5-HT
(2.7360.01 mM) has been taken from Thompson et al. (2006) [26].
Discussion
In the present study we generated five chimeras with different 5-
HT3A receptor sequences of murine and human origin to
determine the structural basis for clozapine binding. Analysis of
5-HT activation curves and clozapine inhibition curves using the
Cheng-Prusoff equation revealed an extracellular sequence (length
86 aa) close to the transmembrane domain M1 which strongly
determines the binding affinity of clozapine. These results suggest
that genetic variations within this sequence of the 5-HT3 receptor
gene may contribute to the antipsychotic potency and/or the side
effect profile of clozapine under clinical conditions.
There is now good evidence that both homomeric (5-HT3A) and
heteromeric (5-HT3AB) 5-HT3 receptor isoforms exist in brain and
peripheral neuronal tissue [9,36]. However, electrophysiological
and immunohistochemical evidence indicates that the majority of
native 5-HT3 receptor complexes do not contain the 5-HT3B
subunit [36,37]; for review see [38]. Moreover, the 5-HT3B subunit
does not contribute to the ligand-binding site [39]. Therefore, we
focussed only on homomeric 5-HT3A receptors in the present study.
The amino acid sequence of the human 5-HT3A receptor
displays 85% identity with the mouse subunits [40]. In contrast to
guinea pig receptors, murine and human 5-HT3 receptors exhibit
a somewhat similar pharmacological profile [25]. The human and
the mouse receptor differ only marginally in their affinity to the
natural ligand 5-HT [14,25,33,34] which could also be confirmed
in the present study. However, both homo-oligomeric receptor
types show remarkable differences with regard to receptor kinetics
and clozapine affinity. Human 5-HT3A receptors are characterised
by a lower charge transfer due to faster desensitization and
deactivation kinetics and a more pronounced receptor desensiti-
zation (see also [25]). Furthermore, repeated activation of human
5-HT3A receptors produced a marked decline in charge transfer.
Currents through mouse receptors are less affected. These
differences in rundown kinetics can be best explained by a
considerable acceleration of desensitization kinetics and plateau
currents for human 5-HT3A receptors, whereas these parameters
are only marginally affected in mouse 5-HT3A receptors.
Moreover, with regard to pharmacology, the competitive antag-
onist clozapine more potently inhibits currents through mouse 5-
HT3A receptors which is reflected by a 10-fold smaller IC50 value
than that obtained for human 5-HT3A receptors (see also [5,24]).
These functional and pharmacological differences may be
valuable for locating sequences important for rundown kinetics
induced by repeated receptor activation and for clozapine binding
affinity by creating human/mouse 5-HT3A receptor chimeras.
The extracellular domain, which forms the ligand binding site
[32,41], appears to be crucial for these functions. In the present
study we therefore constructed three chimeric receptors (C123,
C123, C123) with an extracellular domain combined of human
and murine sequences allowing a more detailed mapping of
determinants of the agonist and antagonist binding site.
The frequent activation of 5-HT3A receptors is accompanied by
constant rundown kinetics reflected by a pronounced acceleration
of tdes1 and tdes2 and a strong reduction of the steady-state current.
Although the peak amplitude also decreased after multiple 5-HT
applications, this effect is less prominent. Thus, the charge transfer
is the most suitable parameter for assessing receptor activity.
Analysis of rundown kinetics revealed a significantly smaller
decline in charge transfer for murine receptors compared to
human and all chimeric receptors. This decline is predominantly
due to a pronounced receptor desensitization after repeated
activation, as plateau currents are reduced to a similar degree.
Since human and murine receptors recovered almost completely
when two 5-HT applications were separated by a 25 sec interval
(data not shown), the use of a 90 sec interval should not affect
receptor desensitization and should prevent consecutive accumu-
lation of desensitization. Interestingly, a similar rundown is
observed for both human and murine 5-HT3 receptors after only
two 5-HT applications separated by a 40 min interval. Thus, the
rundown cannot be simply attributed to an enhancement of
receptor desensitization induced by multiple 5-HT applications.
The analysis of the kinetic and rundown characteristics of all
chimeras did not unravel a clear sequence correlation. Single
Table 2. Differences in rundown with regard to peak
amplitude after multiple activation for human, murine and
chimeric receptors.





C123 N N N
C123 N N N N N
C123 N N N N N
Significant differences (p,0.05, ANOVA) are indicated by black circles.
doi:10.1371/journal.pone.0006715.t002
Table 3. Differences in rundown with regard to charge after
multiple activation for human, murine and chimeric receptors.





C123 N N N N
C123 N N N N
C123 N N N N
Significant differences (p,0.05, ANOVA) are indicated by black dots.
doi:10.1371/journal.pone.0006715.t003
5-HT3 Receptor and Clozapine
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6715
activation of C123 and C123 produced receptor kinetics similar to
murine receptors, whereas repeated activation of these chimeras
induced strong rundown kinetics. Conversely, likewise murine
receptors, the chimera C123 showed only a marginal reduction in
charge transfer after repeated activation but kinetics similar to
human receptors. These results indicate that the molecular
determinants responsible for rundown kinetics and for receptor
desensitization are not associated with the same protein segment.
5-HT activates human and mouse 5-HT3A receptors with
similar potency suggesting that the EC50 values for chimeras
should not differ significantly. However, when considering the
EC50 for charge and peak, 5-HT was significantly more potent in
activating the chimeras C123 and C123 compared to C123 and
C123. A plausible explanation for this inconsistency might be that
the extracellular domain is not the single determinant for agonist
affinity. This hypothesis is supported by a recent investigation
demonstrating that a mutation in the cytoplasmic domain (P391R)
can also cause alterations in agonist binding [26]. Moreover,
irrespective of sequence composition, desensitization and deacti-
vation parameters of chimeric receptors were constantly slower
than the fast human receptor kinetics (see table 1). These
observations cannot be explained by a simple sequence-to-function
correlation. There is evidence that the extracellular domain
determines agonist binding [32,41] whereas the cytoplasmic
domain of the 5-HT3A receptor contributes to a receptor
desensitization mechanism [25,42,43,44]. Concerning the molec-
ular parameters for agonist affinity, receptor kinetics and rundown,
our data rather favour the hypothesis of an involvement of the
tertiary and quaternary structure of the whole receptor molecule
than a restricted structural domain [32]. It is likely that the
Figure 5. 5-HT affinity and functional antagonistic properties of the atypical antipsychotic clozapine against H123 and M123
currents. (A) Human and murine 5-HT3 receptors showed almost identical affinity to 5-HT. (B) Clozapine antagonised 5-HT activated currents
through human and murine 5-HT3 receptors with different potencies, allowing the identification of the structural domains involved in the ligand
recognition for clozapine by human/murine chimeras.
doi:10.1371/journal.pone.0006715.g005
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successful spatial coupling of the neurotransmitter binding site to the
ion channel and cytoplasmic domain is crucial for mediating 5-HT
binding, kinetics and rundown properties. This assumption is
supported by the fact that a P391R point mutation in the
cytoplasmic domain of the 5-HT3 receptor affects the agonist
binding site by increasing the EC50 for 5-HT [35,26]. Since the
rapid desensitization of 5-HT3A receptors during sustained
activation [45,46,47,48] has great importance for synaptic regula-
tion [16], alterations of the tertiary and quaternary structure may
also have implications in the pathophysiology of schizophrenia.
Clozapine potently antagonises murine [24] and human 5-
HT3A receptors [5] with a 10-fold higher affinity against murine
receptors. The evaluation of the antagonistic potency of clozapine
against chimeric receptors revealed IC50 values below the IC50 for
human receptors and for C123 and C123 IC50 levels even below
those of murine receptors. As clozapine is a competitive
antagonist, calculation of true dissociation constant Kb values for
each receptor needs the consideration of the specific 5-HT affinity.
Estimation of Kb values for clozapine using the Cheng-Prusoff
relationship revealed that sequence 2 of the extracellular ligand
binding site (length 86 aa) close to the transmembrane domain M1
strongly determines the binding affinity of clozapine. When
chimeric receptors contain the murine sequence 2 (C123, C123,
C123), their Kb values for clozapine affinity were similar to the Kb
for murine receptors and significantly lower (0.3–1.1 nM)
compared to the chimeras C123, C123 containing the human
sequence 2 with Kb values of 5.8 and 13.4 nM, respectively.
In contrast to other 5-HT receptors, the HTR3A gene shows a
relatively high variability in the coding region, and it is possible
that approximately 1% of schizophrenic patients carry 5-HTR3A
mutations [35]. Approximately 30–60% of all schizophrenic
patients fail to respond to typical antipsychotics [49] and hence,
clozapine may be a valuable treatment alternative. The concen-
trations of clozapine in the cerebrospinal fluid under therapeutical
conditions range from 70–130 nM. Genetic variations in the
primary sequence of 5-HT3 receptors may be crucial for the
antipsychotic potency and/or the side effect profile of clozapine in
that they may determine the antagonistic properties against this
ligand-gated ion channel. Recently, a missense mutation P391R
residing in the highly conserved cytoplasmic region has been
found, which probably only occurs in schizophrenic patients [35].
Figure 6. (A, B) 5-HT-induced currents through chimeric receptors. All
chimeric receptors were dose-dependently activated by 5-HT. For each
dose-response curve values were normalized to the responses induced
by 300 mM 5-HT. Dose-response curves for amplitude (A) and charge (B).
doi:10.1371/journal.pone.0006715.g006
Table 4. Potency of serotonin for human, mouse and
chimeric 5-HT3A receptors against peak amplitude.







C123 N N N N N N
Significant differences (p,0.05, ANOVA) are indicated by black dots.
Comparisons of EC50 for peak amplitude.
doi:10.1371/journal.pone.0006715.t004
Table 5. Potency of serotonin for human, mouse and
chimeric 5-HT3A receptors against charge.






C123 N N N N N
C123 N N N N N
Significant differences (p,0.05, ANOVA) are indicated by black dots.
Comparisons of EC50 for charge (B).
doi:10.1371/journal.pone.0006715.t005
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Figure 7. Antagonistic properties of clozapine against chimeric and mutant receptors. All 5-HT-induced currents through chimeric
receptors and the P391R mutant were dose-dependently reduced by clozapine in a competitive manner, however, with different potencies.
Representative traces for the control and the effects of different concentrations of clozapine on chimeric 5-HT3 receptor-mediated currents. The
application duration of 5-HT was 2 s.
doi:10.1371/journal.pone.0006715.g007
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The functional characterization of these mutants revealed a
significant increase in the EC50 for 5-HT of the P391R mutant
[26]. Consequently, this mutation may thereby also affect
clozapine pharmacology. In fact, the experiments with the
P391R mutant revealed a considerable increase in the antagonistic
potency of clozapine. Furthermore, the calculation of Kb for
clozapine demonstrates that the intracellularly located point
mutation affects the extracellular binding for clozapine via two
mechanisms: either directly by increasing the binding affinity and/
or indirectly by decreasing the EC50 for 5-HT.
In previous studies, two novel 5-HT3A polymorphisms, 178-T/C
and 1596-A/G, have been reported [50]. These polymorphisms
were not related to the therapeutic response to clozapine [50].
However, these polymorphisms are located outside the domain
identified in our study. On the other hand, a polymorphism in the
large intracellular domain region within the 5-HT3A receptor gene
has recently been shown to affect the clinical response to risperidone
treatment [51]. Although the genetic findings available so far
suggest a putative role of the 5-HT3A receptor gene in the
pathophysiology of schizophrenia and the response to antipsychotic
treatment, no data are available on genetic variants within the
extracellular domain of this receptor in schizophrenic patients. As
such, based on our results further genetic studies should look more
closely at the respective sequence responsible for clozapine affinity
Figure 8. (A, B) Antagonistic properties of clozapine against chimeric
and mutant receptors. All 5-HT-induced currents through chimeric
receptors and the P391R mutant were dose-dependently reduced by
clozapine in a competitive manner, however, with different potencies.
Dose-response curves for amplitude (A) and charge (B).
doi:10.1371/journal.pone.0006715.g008
Table 6. Potency of clozapine for human and murine 5-HT3A
receptors and different 5-HT3A receptor chimeras against peak
amplitude.







H123 N N N
Significant differences (p,0.05, ANOVA) are indicated by black dots.
Comparisons of IC50 for peak amplitude.
doi:10.1371/journal.pone.0006715.t006
Table 7. Potency of clozapine for human and murine 5-HT3A
receptors and different 5-HT3A receptor chimeras against
charge.







H123 N N N
Significant differences (p,0.05, ANOVA) are indicated by black dots.
Comparisons of IC50 for peak charge.
doi:10.1371/journal.pone.0006715.t007
Table 8. Calculation of the dissociation constant Kb of
clozapine using the Cheng-Prusoff equation.
receptor Kb clozapine (nM) EC50 5-HT (mM) IC50 clozapine (nM)
C123 0.3 2.7660.26 1.5260.00
C123 0.8 1.3560.12 6.3760.00
M123 0.9 1.2260.13 8.0560.10
C123 1.1 0.6560.02 18.5960.11
P391R 1.3 2.7360.06 5.9260.1
C123 5.8 0.9660.06 65.8560.01
H123 9.2 1.2460.08 83.3260.02
C123 13.4 2.7660.08 62.1760.01
The lowest Kb for clozapine were calculated for receptors containing the murine
sequence 2 (0.3–1.1 nM). When 5-HT3 receptors contained the human sequence
2, clozapine affinity to the binding site was less potent and Kb ranged from 5.8–
13.4 nM. These data demonstrate that the sequence between restriction site
BstEII and SgrA1 (defined as sequence 2) of 5-HT3 receptors is important for the
binding affinity of clozapine. The calculation of the dissociation constant of
clozapine for the P391R mutant revealed a Kb of 1.3 nM. The EC50 for 5-HT
(2.7360.01 mM) has been taken from Thompson et al. (2006) [26].
doi:10.1371/journal.pone.0006715.t008
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to the 5-HT3A receptor identified in the present study by detailed
fine mapping strategies. The therapeutic relevance of the 5-HT3
receptor in schizophrenia has recently been underlined by a
placebo-controlled study with the 5-HT3 receptor antagonist
ondansetron as an add-on medication to a stable dose of risperidone
[52], which showed a positive effect of ondansetron on negative
symptoms and cognitive impairment.
Taken together, these studies suggest that the 5-HT3A receptor
may contribute to the therapeutic efficacy of clozapine in
schizophrenia and that the extracellular sequence close to the
transmembrane domain TM1 within the 5-HT3A receptor
identified in the present study may play a role for the unique
pharmacological profile of clozapine.
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